Relationship between lymphocyte and clinical steroid responsiveness in focal segmental glomerulosclerosis

被引:11
作者
Briggs, WA [1 ]
Gimenez, LF [1 ]
Samaniego-Picota, M [1 ]
Choi, MJ [1 ]
Nadasdy, T [1 ]
Eustace, J [1 ]
Scheel, PJ [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD 21205 USA
关键词
D O I
10.1177/00912700022008757
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A remission in nephrotic proteinuria with steroid treatment appears to favorably alter the natural history of focal segmental glomerulosclerosis (FSGS). It is not known why some patients have a favorable response to steroid treatment whereas others do not. Considering the possibility that differences in the pharmacodynamic responsiveness to steroids among patients might be one factor, the authors examined the relationship between the pretreatment suppressive effect of steroids on lymphocyte proliferation (% inhibition) in vitro and the short- and intermediate-term responses of creatinine clearance (Cl-cr) and/or nephrotic proteinuria (urine protein/creatinine ratio = U-p/c) 13 patients with FSGS. There were significant correlations between % inhibition and the changes in Cl-cr at 3 (r = 0.92, p < 0.001) and 6 (r = 0.86 p < 0.01) months and the changes in U-p/c at 3 months (r = -0.74, p = 0.02). Thus, the greater the pretreatment lymphocyte steroid sensitivity the greater the increase in Cl-cr or decrease in U-p/c. The changes in these parameters could not be accounted for on the basis of steroid dose or histopathology. The in vitro sensitivity of FSGS patients' lymphocytes to steroids may be of value in anticipating their clinical response to treatment. Journal of Clinical Pharmacology, 2000;40:115-123 (C)2000 the American College of Clinical Pharmacology.
引用
收藏
页码:115 / 123
页数:9
相关论文
共 33 条
[1]  
BANFI G, 1991, CLIN NEPHROL, V36, P53
[2]   FOCAL GLOMERULOSCLEROSIS - NATURAL-HISTORY AND TREATMENT - REPORT OF 70 CASES [J].
BEAUFILS, H ;
ALPHONSE, JC ;
GUEDON, J ;
LEGRAIN, M .
NEPHRON, 1978, 21 (02) :75-85
[3]   Lymphocyte responsiveness to glucocorticoids, cyclosporine, or both [J].
Briggs, WA ;
Gao, ZH ;
Gimenez, LF ;
Scheel, PJ ;
Choi, MJ ;
Burdick, JF .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (08) :707-714
[4]  
Briggs WA, 1996, PERITON DIALYSIS INT, V16, P406
[5]   Suppression of lymphocyte interleukin-2 receptor expression by glucocorticoids, cyclosporine, or both [J].
Briggs, WA ;
Gao, ZH ;
Xing, JJ ;
Gimenez, LF ;
Samaniego, MD ;
Scheel, PJ ;
Choi, MJ ;
Burdick, JF .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (10) :931-937
[6]  
CAMERON JS, 1978, CLIN NEPHROL, V10, P213
[7]  
CATTRAN D, 1995, J AM SOC NEPHROL, V6, P415
[8]   Long-term outcome in children and adults with classic focal segmental glomerulosclerosis [J].
Cattran, DC ;
Rao, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) :72-79
[9]   THE EFFECTS OF HYDROCORTISONE ON IN-VITRO LYMPHOCYTE-PROLIFERATION AND INTERLEUKIN-2 AND INTERLEUKIN-4 PRODUCTION IN CORTICOSTEROID SENSITIVE AND RESISTANT SUBJECTS [J].
CHIKANZA, IC ;
PANAYI, GS .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1993, 23 (12) :845-850
[10]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41